Opvee (Nalmefene HCl) Patent Expiration, LOE Window & CMS Spending

Opvee (Nalmefene HCl) by Indivior: FDA Orange Book LOE 2042-08-04, 0 AB generics, $16K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIndivior
FDA Application & PathwayN217470 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-08-04
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$16K
2024 Medicare Part D Spend$7K
2024 Medicaid Spend$10K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel